These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 20010481)

  • 41. The hepatitis C virus enigma.
    Myrmel H; Ulvestad E; Asjø B
    APMIS; 2009 May; 117(5-6):427-39. PubMed ID: 19400866
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interferon in the treatment of chronic hepatitis C: a drug caught between past and future.
    Vezali E; Aghemo A; Colombo M
    Expert Opin Biol Ther; 2011 Mar; 11(3):301-13. PubMed ID: 21250869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cyclophilin inhibitors for hepatitis C therapy.
    Membreno FE; Espinales JC; Lawitz EJ
    Clin Liver Dis; 2013 Feb; 17(1):129-39. PubMed ID: 23177289
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Antiviral therapy of chronic hepatitis C: 30 years success story].
    Abdurakhmanov DT; Rozina TP; Nikulkina EN; Burnevich EZ; Tanashuk EL; Severov MV; Filatova AL; Milovanova SY; Karpov VV; Moiseev SV
    Ter Arkh; 2019 Nov; 91(11):110-115. PubMed ID: 32598621
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure.
    McGreal N; Jensen DM
    Liver Int; 2009 Apr; 29(4):481-2. PubMed ID: 19323778
    [No Abstract]   [Full Text] [Related]  

  • 46. Current and future therapy for chronic hepatitis C virus liver disease.
    Lake-Bakaar G
    Curr Drug Targets Infect Disord; 2003 Sep; 3(3):247-53. PubMed ID: 14529357
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Viral resistance in HCV infection.
    Ceccherini-Silberstein F; Cento V; Di Maio VC; Perno CF; Craxì A
    Curr Opin Virol; 2018 Oct; 32():115-127. PubMed ID: 30439589
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
    Korba BE; Elazar M; Lui P; Rossignol JF; Glenn JS
    Antimicrob Agents Chemother; 2008 Nov; 52(11):4069-71. PubMed ID: 18710916
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The molecular biology of hepatitis C virus].
    Koutsoudakis G; Forns X; Pérez-Del-Pulgar S
    Gastroenterol Hepatol; 2013 Apr; 36(4):280-93. PubMed ID: 23490024
    [TBL] [Abstract][Full Text] [Related]  

  • 50. New treatments for chronic hepatitis C: an overview for paediatricians.
    Serranti D; Indolfi G; Resti M
    World J Gastroenterol; 2014 Nov; 20(43):15965-74. PubMed ID: 25473150
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Virology of hepatitis C virus infection.
    Chevaliez S; Pawlotsky JM
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):381-9. PubMed ID: 23199498
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hepatitis C virus: molecular biology & current therapeutic options.
    Sharma SD
    Indian J Med Res; 2010 Jan; 131():17-34. PubMed ID: 20167971
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Second generation direct antivirals and the way to interferon-free regimens in chronic HCV.
    Lewis H; Cunningham M; Foster G
    Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):471-85. PubMed ID: 23199506
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets.
    Ploss A; Dubuisson J
    Gut; 2012 May; 61 Suppl 1():i25-35. PubMed ID: 22504917
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Entry inhibitors: New advances in HCV treatment.
    Qian XJ; Zhu YZ; Zhao P; Qi ZT
    Emerg Microbes Infect; 2016 Jan; 5(1):e3. PubMed ID: 26733381
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hepatitis C virus therapies: current treatments, targets and future perspectives.
    Walker MP; Appleby TC; Zhong W; Lau JY; Hong Z
    Antivir Chem Chemother; 2003 Jan; 14(1):1-21. PubMed ID: 12790512
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-HCV drugs in the pipeline.
    Yang PL; Gao M; Lin K; Liu Q; Villareal VA
    Curr Opin Virol; 2011 Dec; 1(6):607-16. PubMed ID: 22440918
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hepatitis C Virus and Antiviral Drug Resistance.
    Kim S; Han KH; Ahn SH
    Gut Liver; 2016 Nov; 10(6):890-895. PubMed ID: 27784846
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anti-hepatitis C virus drugs in development.
    Schaefer EA; Chung RT
    Gastroenterology; 2012 May; 142(6):1340-1350.e1. PubMed ID: 22537441
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?
    Chatterjee A; Guedj J; Perelson AS
    Antivir Ther; 2012; 17(6 Pt B):1171-82. PubMed ID: 23186606
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.